Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

146
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
The Ras Gene02:38

The Ras Gene

6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

K-Ras controls asymmetric cell divisions from the primary cilium.

Cell death & disease·2026
Same author

Molecular mechanisms of transhydrogenase activity and allosteric regulation in eukaryotic type II PHGDH Ser33.

Nature communications·2026
Same author

ZFHX4 is necessary for dopaminergic neuron differentiation and controls cell cycle by regulating LIN28A.

Stem cell reports·2026
Same author

SARS-CoV-2 Infection Induces Dopaminergic Neuronal Loss in Midbrain Organoids.

Journal of neurochemistry·2026
Same author

Cooperative Binding Domains Enhance Sensitivity and Overcome the Hook Effect in Two-Component Protein Biosensors.

ACS sensors·2026
Same author

Identification of Circulating MiR-4651 as Novel Biomarker for Metabolic Dysfunction-Associated Steatotic Liver Disease.

Gastro hep advances·2026

Related Experiment Video

Updated: Jun 26, 2025

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

8.6K

An Improved PDE6D Inhibitor Combines with Sildenafil To Inhibit KRAS Mutant Cancer Cell Growth.

Pelin Kaya1, Elisabeth Schaffner-Reckinger1, Ganesh Babu Manoharan1

  • 1Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, 4365 Esch-sur-Alzette, Luxembourg.

Journal of Medicinal Chemistry
|May 17, 2024
PubMed
Summary

Researchers developed Deltaflexin3, a highly soluble PDE6D inhibitor, to target K-Ras in cancer. This new inhibitor shows reduced off-target effects and effectively inhibits cancer cell growth, offering a promising therapeutic strategy.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.2K

Related Experiment Videos

Last Updated: Jun 26, 2025

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

8.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Phosphodiesterase 6D (PDE6D) is a chaperone protein involved in K-Ras trafficking.
  • Previous K-Ras targeting strategies via PDE6D inhibition faced challenges with solubility and off-target effects.
  • Developing effective PDE6D inhibitors is crucial for targeting KRAS-mutant cancers.

Purpose of the Study:

  • To develop a highly soluble and selective PDE6D inhibitor.
  • To evaluate the efficacy of the novel inhibitor, Deltaflexin3, in reducing cancer cell proliferation.
  • To explore combination therapy with PDE6D inhibition and PKG2 activation.

Main Methods:

  • Synthesis and characterization of Deltaflexin3, a novel PDE6D inhibitor.
  • Assessment of inhibitor solubility and off-target activity compared to reference compounds.
  • In vitro and in vivo studies on KRAS-mutant cancer cells and microtumors.
  • Investigation of PKG2-mediated phosphorylation's role in K-Ras/PDE6D interaction.

Main Results:

  • Deltaflexin3 demonstrated high solubility and significantly lower off-target activity than existing inhibitors.
  • Deltaflexin3 effectively reduced Ras signaling and selectively inhibited the growth of KRAS-mutant and PDE6D-dependent cancer cells.
  • Combination of Deltaflexin3 with Sildenafil (a PKG2 activator) enhanced inhibition of PDE6D/K-Ras binding, cancer cell proliferation, and microtumor growth.

Conclusions:

  • Deltaflexin3 represents a promising, highly soluble, and selective PDE6D inhibitor for cancer therapy.
  • The combination of Deltaflexin3 and Sildenafil offers a potent strategy for targeting KRAS-mutant cancers.
  • Re-evaluation of PDE6D as a K-Ras surrogate target is warranted based on these findings.